Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Kommende kliniske studier
-
Zheng LiHar ikke rekruttert ennåKognitiv skrøpelighet
-
Techpool Bio-Pharma Co., Ltd.Har ikke rekruttert ennå
-
Istanbul University - CerrahpasaRekrutteringCerebral pareseTyrkia (Türkiye)
-
Project Skin MDHar ikke rekruttert ennå
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Har ikke rekruttert ennåAkutt iskemisk slag AIS
-
Hospital Universitario La PazHar ikke rekruttert ennåNasal obstruksjon | Bronkiolitt | Akutte øvre luftveisinfeksjonerSpania
-
E-DA HospitalNational Cheng Kung University; Metal Industries Research & Development...RekrutteringObstruktiv søvnapnéTaiwan
-
Assistance Publique - Hôpitaux de ParisHar ikke rekruttert ennåEkstrakorporeal membran oksygeneringskomplikasjon | ECMO Cannula InfectionFrankrike
-
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.RekrutteringBrystkreft | Magekreft | Eggstokkreft | Avanserte solide svulster | Andre solide svulsterKina
-
Gustave Roussy, Cancer Campus, Grand ParisHar ikke rekruttert ennåAdult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 GeneFrankrike
-
Assistance Publique - Hôpitaux de ParisRekrutteringAttention Deficit DisorderFrankrike
-
University GhentHar ikke rekruttert ennåPostoperativ smerte, akutt | Irreversibel pulpitt (tannpine) | Pulp Necrosis, Apical PeriodontitisBelgia
Clinical Research Jobs
-
Italy - Milan
-
United States - Shrewsbury
-
United Kingdom - Leeds
-
India - Kochi
-
United States - Massachusetts - Boston
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China